Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.
Journal: Nature communications
Published: August 01, 2022
Cutting Edge: Effect of Disease-Modifying Therapies on SARS-CoV-2 Vaccine-Induced Immune Responses in Multiple Sclerosis Patients.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: December 08, 2021
Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: November 14, 2019
Corrigendum to 'Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (2014) 1958-1971].
Journal: Clinical therapeutics
Published: March 11, 2018
Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype.
Journal: Clinical immunology (Orlando, Fla.)
Published: February 08, 2018
S1P1 deletion differentially affects TH17 and Regulatory T cells.
Journal: Scientific reports
Published: November 28, 2016
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 26, 2016
Distinct T cell signatures define subsets of patients with multiple sclerosis.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: June 01, 2016
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
Journal: Neurology
Published: February 15, 2015
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
Journal: Clinical therapeutics
Published: January 13, 2015
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.
Journal: Annals of clinical and translational neurology
Published: May 16, 2014
Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
Journal: Clinical therapeutics
Published: March 24, 2014
Last Updated: 09/26/2026